Emoksipin

General characteristics. Structure:

Active agent: a metiletilpiridinola a hydrochloride - 30 mg;

Excipients: solution of sodium of hydroxide of 1 M to рН 4,8 - 5,8; water for injections to 1 ml.

Pharmacological properties:

Emoksipin - antioxidant. Emoksipin reduces permeability of a vascular wall, is inhibitor of free radical processes, anti-hypoxanthomas and antioxidant.
Reduces viscosity of blood and aggregation of thrombocytes, increases the maintenance of cyclic nucleotides (cyclic adenosinemonophosphate and cyclic гуанозинмонофосфат) in thrombocytes and tissue of a brain, has fibrinolitic activity, reduces permeability of a vascular wall and a risk degree of development of hemorrhages, promotes their rassasyvaniye.
Expands coronary vessels, in the acute period of a myocardial infarction limits necrosis center size, improves sokratitelny ability of heart and function of its carrying-out system.
With the increased arterial pressure renders hypotensive effect. At acute ischemic disorders of cerebral circulation reduces weight of neurologic symptomatology, increases resistance of fabric to a hypoxia and ischemia.
Has retinoprotektorny properties, protects a retina from the damaging effect of light of high intensity, promotes a rassasyvaniye of intraocular hemorrhages, improves microcirculation of an eye.

Indications to use:

- Subconjunctival and intraocular hemorrhage of various genesis.
- Angioretinopatiya (including diabetic retinopathy).
- Central and peripheral chorioretinal dystrophy.
- Thrombosis of the central vein of a retina and its branches.
- Myopia complications.
- Angiosclerotic makulodistrofiya (dry form).
- Operative measures in the eyes, a state after operation for glaucoma with choroid amotio.
- Dystrophic diseases of a cornea.
- Injury, inflammation and burn of a cornea.
- Protection of a cornea (when carrying contact lenses) and eye retinas from influence of light of high intensity (laser and sunblisters, at a lazerokoagulyation).

Route of administration and doses:

Solution of an emoksipin is entered subkonjyunktivalno or parabulbarno. If necessary perhaps retrobulbar introduction. Subkonjyunktivalno is entered on 0,2-0,5 ml (2-5 mg), parabulbarno - 0,5-1 ml (5-10 mg) of 1% of solution. Drug is used once a day or every other day within 10-30 days. If necessary it is possible to repeat treatment 2-3 times a year. Retrobulbarno enter on 0,5-1 ml 1% of solution within 10-15 days once a day.
For protection of a retina at a lazerokoagulyation (including at the limiting and destroying coagulation of tumors) - parabulbarno or retrobulbarno on 0,5-1 ml of 1% of solution for 24 h and for 1 h before coagulation; then - the same doses (on 0,5 ml of 1% of solution) 1 time a day within 2-10 days.

Features of use:

Treatment should be carried out under control of arterial pressure and coagulability of blood.

Side effects:

Short-term excitement, drowsiness, increase in arterial pressure, allergic reactions (skin rashes, etc.).
Local reactions: pain, burning, an itch, a hyperemia, consolidation of paraorbital fabrics (resolves independently).

Interaction with other medicines:

Pharmaceutical it is incompatible with other medicines.

Contraindications:

- The increased individual sensitivity to drug.
- Pregnancy, lactation.
- Children up to 18 years.

Use at pregnancy and feeding by a breast
Use at pregnancy and feeding by a breast is contraindicated.

Overdose:

There are no data.

Storage conditions:

To store in the place protected from light, at a temperature not above 25 °C.

Issue conditions:

According to the recipe

Packaging:

In an ampoule of 1 ml of 1% of solution for injections. In strip planimetric packaging of 5 ampoules. In a cardboard pack 2 packagings.